Alzheimer's Disease Stocks List

Alzheimer's Disease Stocks Recent News

Date Stock Title
Nov 22 PFE Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
Nov 22 PFE BridgeBio heart drug approved by FDA, setting up battle with Pfizer
Nov 22 PFE Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
Nov 22 PFE FDA Accepts Bayer's Application for Label Expansion of Nubeqa
Nov 22 PFE Pfizer Inc. (PFE) Jefferies London Healthcare Conference (Transcript)
Nov 22 PFE Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
Nov 22 PFE RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?
Nov 22 PFE Zai Lab and Pfizer to commercialise XACDURO in China
Nov 22 PFE The Irish Government Is Unbelievably Rich. It’s Largely Thanks to Uncle Sam.
Nov 21 PFE Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
Nov 21 ACAD Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Nov 21 PFE Optimism over global healthcare sector rises: Jefferies
Nov 21 PFE Major companies that are also popular short-selling stocks
Nov 21 PFE 5 Best Value Stocks With Discounted PEG to Boost Your Portfolio Return
Nov 21 PFE The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair
Nov 21 PFE Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Nov 21 PFE 2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Nov 21 PFE EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
Nov 21 PFE 2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Nov 20 PFE CDC warns of an imminent spike in COVID, flu cases
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags